Large Chinese pharma group making traditional Chinese medicine and generic drugs, with a nationwide pharmacy retail/distribution network.
Large Chinese pharma group making traditional Chinese medicine and generic drugs, with a nationwide pharmacy retail/distribution network.
Distribution of other makers' drugs brings in a large share of revenue but little of the profit, while its own traditional-medicine and generic-drug factories, the pharmacy chain and the Wanglaoji herbal-tea brand carry the margins. This is the Hong Kong listing of the company trading in Shanghai as 600332.SS. Guangzhou's state-owned pharmaceutical group controls it.
In one line: A Chinese CVS Health plus a generic-drug maker.
Moat: narrow (brand, distribution, scale). Century-old TCM brands and one of China's largest pharmacy distribution networks.
Headquarters: Guangzhou, China · Founded: 1997 · Employees: 27,057
Size Guangzhou Baiyunshan Pharmaceutical (0874.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $4.48B, the 268th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$12.55 on 18 Nov 2026.
Performance Over six months the shares fell 22.6%, against +10.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +10.2%); the operating margin is 3.1% (peer median 17.1%).
Valuation It trades at 7.0× forward earnings against a peer median of 29.9× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.5 points below its cost of capital (6.1% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$88.8B | HK$84.0B | HK$81.1B | HK$83.1B | HK$82.0B |
| Revenue growth | — | +4% | -2% | +1% | — |
| Gross profit | HK$13.8B | HK$12.8B | HK$12.7B | HK$14.6B | HK$14.4B |
| EBITDA | n/a | HK$4.40B | HK$4.65B | HK$6.01B | HK$5.59B |
| Net income | HK$2.47B | HK$3.24B | HK$3.07B | HK$4.48B | HK$4.61B |
| Free cash flow | HK$1.59B | -HK$1.06B | HK$2.74B | HK$3.16B | HK$6.78B |
| Capital expenditure | HK$1.24B | HK$1.34B | HK$1.22B | HK$1.80B | HK$1.61B |
| Total debt | HK$27.2B | HK$23.0B | HK$19.7B | HK$17.4B | HK$17.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
| China Medical System 0867.HK | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0874.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | +0.7% | 7th lowest of 21 |
| 6-month return | -22.6% | +10.4% | 3rd lowest of 20 |
| Distance from 52-week high | -38.5% | -32.7% | 8th lowest of 21 |
| Revenue growth (TTM) | +6.0% | +10.2% | 9th lowest of 19 |
| Operating margin | 3.1% | 17.1% | 3rd lowest of 19 |
| Forward P/E | 7.0× | 29.9× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.3% | 7.3% | 5th least demanding of 17 |
| Growth delivered (Del g) | +4.0% | +10.9% | 5th lowest of 17 |
| Hurdle (Req g minus delivered) | -2.7 pp | -3.7 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | -1.5 pp | +5.6 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |